[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1414809T3 - Indaneddikesyrederivater og anvendelse deraf som farmaceutiske midler, mellemprodukter og fremgangsmåder til fremstilling deraf - Google Patents

Indaneddikesyrederivater og anvendelse deraf som farmaceutiske midler, mellemprodukter og fremgangsmåder til fremstilling deraf

Info

Publication number
DK1414809T3
DK1414809T3 DK02750297T DK02750297T DK1414809T3 DK 1414809 T3 DK1414809 T3 DK 1414809T3 DK 02750297 T DK02750297 T DK 02750297T DK 02750297 T DK02750297 T DK 02750297T DK 1414809 T3 DK1414809 T3 DK 1414809T3
Authority
DK
Denmark
Prior art keywords
pharmaceuticals
intermediates
processes
preparation
acid derivatives
Prior art date
Application number
DK02750297T
Other languages
English (en)
Inventor
Philip D G Coish
Ingo A Mugge
Andreas Stolle
Ming Wang
Derek B Lowe
Philip L Wickens
Xin Ma
Mingbao Zhang
William H Bullock
Yamin Wang
Chengzhi Zhang
Hai-Jun Zhang
Lei Zhu
Manami Tsutsumi
James N Livingston
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Application granted granted Critical
Publication of DK1414809T3 publication Critical patent/DK1414809T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C07C51/44—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation by distillation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK02750297T 2001-07-27 2002-07-25 Indaneddikesyrederivater og anvendelse deraf som farmaceutiske midler, mellemprodukter og fremgangsmåder til fremstilling deraf DK1414809T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30850001P 2001-07-27 2001-07-27
US37304802P 2002-04-16 2002-04-16
PCT/US2002/023614 WO2003011842A1 (en) 2001-07-27 2002-07-25 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation

Publications (1)

Publication Number Publication Date
DK1414809T3 true DK1414809T3 (da) 2008-06-23

Family

ID=26976280

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02750297T DK1414809T3 (da) 2001-07-27 2002-07-25 Indaneddikesyrederivater og anvendelse deraf som farmaceutiske midler, mellemprodukter og fremgangsmåder til fremstilling deraf

Country Status (33)

Country Link
US (4) US6828335B2 (da)
EP (1) EP1414809B1 (da)
JP (1) JP4510447B2 (da)
KR (2) KR100987267B1 (da)
CN (1) CN100528850C (da)
AR (1) AR036237A1 (da)
AT (1) ATE388944T1 (da)
AU (2) AU2002319693B2 (da)
BR (1) BR0211502A (da)
CA (2) CA2753329A1 (da)
CO (1) CO5560561A2 (da)
CY (1) CY1107370T1 (da)
DE (1) DE60225561T2 (da)
DK (1) DK1414809T3 (da)
ES (1) ES2302825T3 (da)
HK (2) HK1073653A1 (da)
HR (1) HRP20040076A2 (da)
HU (1) HUP0700105A2 (da)
IL (3) IL159960A0 (da)
MA (1) MA27063A1 (da)
MX (1) MXPA04000599A (da)
MY (1) MY139541A (da)
NO (2) NO20040356L (da)
NZ (1) NZ531351A (da)
PE (1) PE20030326A1 (da)
PL (1) PL374383A1 (da)
PT (1) PT1414809E (da)
RU (1) RU2314298C2 (da)
SI (1) SI1414809T1 (da)
SV (1) SV2003001186A (da)
TW (2) TWI345563B (da)
UY (1) UY27392A1 (da)
WO (1) WO2003011842A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US20110065129A1 (en) * 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AU2003263814A1 (en) * 2002-07-26 2004-02-16 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
DE60336264D1 (de) 2002-12-20 2011-04-14 Bayer Pharmaceuticals Corp Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel sowie zwischenprodukte und methoden zu ihrer herstellung
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
JPWO2005110394A1 (ja) * 2004-05-19 2008-03-21 味の素株式会社 糖尿病治療薬
WO2006018855A1 (en) * 2004-08-20 2006-02-23 Cadila Healthcare Limited Novel antidiabetic compounds
WO2006057448A1 (ja) * 2004-11-26 2006-06-01 Takeda Pharmaceutical Company Limited アリールアルカン酸誘導体
MX2008012529A (es) 2006-03-30 2008-10-14 Asahi Kasei Pharma Corp Derivado biciclico substituido y uso del mismo.
GB0712653D0 (en) 2007-06-28 2007-08-08 Syngenta Ltd Novel herbicides
GB0717082D0 (en) 2007-09-03 2007-10-10 Syngenta Ltd Novel herbicides
JP5198560B2 (ja) 2008-04-28 2013-05-15 旭化成ファーマ株式会社 フェニルプロピオン酸誘導体及びその用途
WO2009157173A1 (ja) * 2008-06-23 2009-12-30 トーアエイヨー株式会社 経皮吸収促進剤及びこれを用いた経皮投与製剤
KR20110082145A (ko) * 2008-10-21 2011-07-18 메타볼렉스, 인코포레이티드 아릴 ｇｐｒ１２０ 수용체 작동약 및 이의 용도
CN102333528B (zh) * 2009-01-26 2013-12-18 台北医学大学 蕨素化合物用于治疗糖尿病及肥胖之用途
AR075401A1 (es) 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
WO2010141690A2 (en) * 2009-06-04 2010-12-09 Dara Biosciences, Inc. Indane analogs and use as pharmaceutical agents and process of making
US20120141483A1 (en) * 2009-06-04 2012-06-07 Mary Katherine Delmedico Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
US20180200230A1 (en) * 2009-06-04 2018-07-19 Dara Biosciences, Inc. Methods of treating neurodegenerative diseases using indane acetic acid derivatives which penetrate the blood brain barrier
US9334266B2 (en) 2009-09-04 2016-05-10 The University Of Toledo Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
WO2012074980A2 (en) * 2010-12-01 2012-06-07 Dara Biosciences, Inc. Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
KR20170131644A (ko) * 2015-03-26 2017-11-29 티3디 테라퓨틱스, 인크. 인단 아세트산 유도체를 사용한 간 질환의 치료 방법
TWI712582B (zh) * 2015-10-14 2020-12-11 法商領先藥物公司 用來製備(5s,10s)-10-苄基-16-甲基-11,14,18-三側氧基-15,17,19-三氧雜-2,7,8-三噻基-12-氮二十一烷基-5-銨基(e)-3-羧基丙烯酸鹽的工業方法
US20180153859A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype
US20180153860A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives
IL272258B (en) * 2017-07-28 2022-08-01 Chemocentryx Inc Immunomodulator compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929923A (en) * 1972-01-17 1975-12-30 Sun Research Development Process for preparation of isomers of 1-cyclohexyl-1,3,3-trimethylhydrindane
US4754043A (en) * 1985-10-03 1988-06-28 American Home Products Corporation Oxazole and thiazole naphthalenes as antiallergic agents
FR2670491B1 (fr) 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5480896A (en) * 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
JPH1087602A (ja) * 1996-09-09 1998-04-07 Zeria Pharmaceut Co Ltd スルホンアミド誘導体、それを含有するトロンボキサン拮抗剤及び該化合物の製造中間体
AU8750298A (en) * 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
PL351470A1 (en) 1999-04-28 2003-04-22 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
AU7073400A (en) * 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
JP2004509084A (ja) 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento

Also Published As

Publication number Publication date
DE60225561T2 (de) 2009-04-23
HK1098125A1 (en) 2007-07-13
EP1414809A1 (en) 2004-05-06
CA2455620C (en) 2011-12-06
US7112597B2 (en) 2006-09-26
HRP20040076A2 (en) 2005-06-30
EP1414809B1 (en) 2008-03-12
SV2003001186A (es) 2003-03-18
IL208891A0 (en) 2011-01-31
WO2003011842A1 (en) 2003-02-13
AU2008237581A1 (en) 2008-11-20
US6828335B2 (en) 2004-12-07
US20060205723A1 (en) 2006-09-14
CO5560561A2 (es) 2005-09-30
CN100528850C (zh) 2009-08-19
TW201029979A (en) 2010-08-16
US7358386B2 (en) 2008-04-15
UY27392A1 (es) 2003-01-31
NO20083411L (no) 2004-03-19
HUP0700105A2 (en) 2007-09-28
TWI328008B (en) 2010-08-01
US20090047687A1 (en) 2009-02-19
JP4510447B2 (ja) 2010-07-21
CY1107370T1 (el) 2012-12-19
RU2314298C2 (ru) 2008-01-10
AU2002319693B2 (en) 2008-08-07
HK1073653A1 (en) 2005-10-14
ES2302825T3 (es) 2008-08-01
NZ531351A (en) 2006-09-29
ATE388944T1 (de) 2008-03-15
MXPA04000599A (es) 2005-02-17
MY139541A (en) 2009-10-30
KR100956898B1 (ko) 2010-05-11
CN1558905A (zh) 2004-12-29
BR0211502A (pt) 2005-09-20
KR20090125225A (ko) 2009-12-03
DE60225561D1 (de) 2008-04-24
US20050075338A1 (en) 2005-04-07
PT1414809E (pt) 2008-06-04
KR20040028950A (ko) 2004-04-03
MA27063A1 (fr) 2004-12-20
TWI345563B (en) 2011-07-21
KR100987267B1 (ko) 2010-10-12
RU2004105925A (ru) 2005-07-10
IL159960A0 (en) 2004-06-20
IL159960A (en) 2010-12-30
NO20040356L (no) 2004-03-19
PE20030326A1 (es) 2003-04-16
IL208891A (en) 2013-02-28
PL374383A1 (en) 2005-10-17
AR036237A1 (es) 2004-08-25
JP2005508308A (ja) 2005-03-31
CA2455620A1 (en) 2003-02-13
CA2753329A1 (en) 2003-02-13
SI1414809T1 (sl) 2008-08-31
US20030216391A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
DK1414809T3 (da) Indaneddikesyrederivater og anvendelse deraf som farmaceutiske midler, mellemprodukter og fremgangsmåder til fremstilling deraf
DK1448195T3 (da) N-adamantylmethylderivater og mellemprodukter som farmaceutiske præparater og fremgangsmåde til fremstilling deraf
DK1425014T3 (da) Diarylcycloalkylderivater, fremgangsmåde til deres fremstilling og deres anvendelse som PPAR-aktivatorer
DK1368349T3 (da) Xanthinderivater, deres fremstilling og deres anvendelse som lægemidler
NO20035193D0 (no) Nye pyrrolderivater som farmasöytiske midler
DK1294682T3 (da) Acylphenylurinstofderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
DK1017670T3 (da) Benzamidoximderivater, mellemprodukter og fremgangsmåder til deres fremstilling og deres anvendelse som fungicider
DK1427730T3 (da) Nye dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
NO20020811D0 (no) Sulfonylkarboksamidderivater, fremgangsmåte for deres fremstilling og deres anvendelse som legemidler
DK1500654T3 (da) Benzoxazinonderivater, fremstilling deraf og anvendelse deraf som lægemidler
NO20031273L (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
NO994671D0 (no) Aryl- eller heteroarylsulfonamid-substituerte hydroksamsyrederivater, fremgangsmaate til fremstillint derav og deres anvendelse som farmasöytika
NO20006029D0 (no) Pyrazolinderivater, deres fremstilling og anvendelse som legemidler
DK1670458T3 (da) 1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
DK1381605T3 (da) Mercaptoacetylamidderivater, en fremgangsmåde til deres fremstilling og deres anvendelse
DK1045856T3 (da) Nye aromatiske amider, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
DK1246807T3 (da) Hydantoin-, thiohydantoin-, purimidindion- og thioxopyrimidinonderivater, fremgangsmåder til deres fremstilling og deres anvendelse som lægemidler
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
DK1453810T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DK1406899T3 (da) Phenylacetamidothiazolderivater, fremgangsmåder til deres fremstilling og deres anvendelse som antitumormidler
DK1276760T3 (da) Polyamidnukleinsyrederivater, middel og fremgangsmåde til deres fremstilling
NO20031844L (no) Nye askorbinsyreforbindelser, fremgangsmåter for fremstilling derav og anvendelse derav